JPWO2021209174A5 - - Google Patents

Info

Publication number
JPWO2021209174A5
JPWO2021209174A5 JP2022562465A JP2022562465A JPWO2021209174A5 JP WO2021209174 A5 JPWO2021209174 A5 JP WO2021209174A5 JP 2022562465 A JP2022562465 A JP 2022562465A JP 2022562465 A JP2022562465 A JP 2022562465A JP WO2021209174 A5 JPWO2021209174 A5 JP WO2021209174A5
Authority
JP
Japan
Prior art keywords
hydroxy
mutilin
acetyl
cyclohexylsulfanyl
diastereomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522644A (ja
JP2023522644A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/025140 external-priority patent/WO2021209174A1/en
Publication of JP2023522644A publication Critical patent/JP2023522644A/ja
Publication of JP2023522644A5 publication Critical patent/JP2023522644A5/ja
Publication of JPWO2021209174A5 publication Critical patent/JPWO2021209174A5/ja
Priority to JP2025230606A priority Critical patent/JP2026041886A/ja
Pending legal-status Critical Current

Links

JP2022562465A 2020-04-17 2021-04-16 プレウロムチリンの治療的使用 Pending JP2023522644A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025230606A JP2026041886A (ja) 2020-04-17 2025-12-04 プレウロムチリンの治療的使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063011474P 2020-04-17 2020-04-17
EP20170072.1 2020-04-17
US63/011,474 2020-04-17
EP20170072 2020-04-17
EP20183292.0 2020-06-30
EP20183292 2020-06-30
PCT/EP2021/025140 WO2021209174A1 (en) 2020-04-17 2021-04-16 Therapeutic use of pleuromutilins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025230606A Division JP2026041886A (ja) 2020-04-17 2025-12-04 プレウロムチリンの治療的使用

Publications (3)

Publication Number Publication Date
JP2023522644A JP2023522644A (ja) 2023-05-31
JP2023522644A5 JP2023522644A5 (https=) 2025-07-30
JPWO2021209174A5 true JPWO2021209174A5 (https=) 2025-07-30

Family

ID=75801547

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022562465A Pending JP2023522644A (ja) 2020-04-17 2021-04-16 プレウロムチリンの治療的使用
JP2025230606A Pending JP2026041886A (ja) 2020-04-17 2025-12-04 プレウロムチリンの治療的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025230606A Pending JP2026041886A (ja) 2020-04-17 2025-12-04 プレウロムチリンの治療的使用

Country Status (9)

Country Link
US (1) US20230174472A1 (https=)
EP (1) EP4135682A1 (https=)
JP (2) JP2023522644A (https=)
CN (1) CN115443131A (https=)
BR (1) BR112022020007A2 (https=)
CA (1) CA3180535A1 (https=)
IL (1) IL297268A (https=)
TW (1) TW202203908A (https=)
WO (1) WO2021209174A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250134844A1 (en) 2022-02-09 2025-05-01 Nabriva Therapeutics GmbH Therapeutic use of pleuromutilins
EP4338732A1 (en) 2022-09-16 2024-03-20 Nabriva Therapeutics GMBH Lefamulin and its derivatives for use in the treatment of tularemia
CN119925362A (zh) * 2023-11-03 2025-05-06 阳光安津(南京)生物医药科技有限公司 一种化合物在制备用于治疗银屑病的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298733B1 (en) * 2005-06-27 2016-05-25 Nabriva Therapeutics AG Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
EP1972618A1 (en) 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
GB0803707D0 (en) 2008-02-28 2008-04-09 Cambridge Entpr Ltd Antiviral agent
EP2399904A1 (en) * 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
CN103204787B (zh) 2012-01-17 2014-10-01 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
CN103242210B (zh) 2012-02-09 2014-09-24 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
KR102656841B1 (ko) 2015-06-17 2024-04-12 나브리바 테라퓨틱스 게엠베하 레파뮬린의 주사가능한 약제학적 제형
CN110507823B (zh) * 2019-08-20 2021-08-24 中国医学科学院基础医学研究所 衣康酸相关物质在诊断、防治病毒感染性疾病中的应用

Similar Documents

Publication Publication Date Title
JP2010270130A5 (https=)
JP2010285436A5 (https=)
JP2013508282A (ja) ウイルス感染のための併用療法処置
US20180185404A1 (en) Compositions and methods for the treatment of viral infection
JPWO2021209174A5 (https=)
JP2023502053A (ja) デング病の治療及び予防
EP3934653B1 (en) Azelastine as antiviral treatment
EP4167983A1 (en) Antiviral use of calixarenes
CN108472375A (zh) 中重度流感的治疗方法
CN109553554B (zh) 含脲基的神经氨酸酶抑制剂及其医药用途
JP2015524460A5 (https=)
CN116589518B (zh) 一种新型的胞苷衍生物及其药物组合物和用途
JP2011006424A5 (https=)
JP2010189301A (ja) 新型インフルエンザ感染症に対する医薬組成物およびその利用
JP2011513356A5 (https=)
WO2022133494A1 (en) Antiviral compounds and applications thereof
CN118812613A (zh) 4′-氟尿苷类化合物、包含其的药物组合物及其用途
RU2008102655A (ru) Введение в дыхательные пути ингибитора тканевого фактора при воспалительных состояниях, поражающих дыхательные пути
JP2011016804A5 (https=)
JP2025502175A (ja) Ｃｏｖｉｄ－１９の治療のための組成物及び方法
RU2726119C1 (ru) Новые производные полиолов, их применение, фармацевтическая композиция на их основе
CN116589518A (zh) 一种新型的胞苷衍生物及其药物组合物和用途
RU2745265C2 (ru) Новые составы 2-(имидазол-4-ил)-этанамида пентандиовой-1,5 кислоты для лечения и профилактики вирусных заболеваний
WO2025257401A1 (en) Novel isophthalate compounds for the treatment of a viral lung infection
HK40086507A (zh) 用於治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法